Read the full article here:
livewithms.com/blogs/blog/first-generic...
More education and support at livewithms.com
#LiveWithMS #MSAwareness #MultipleSclerosis #Aubagio #MSTreatment #MSMedications #MSCommunity
Read the full article here:
livewithms.com/blogs/blog/infusion-ther...
More education and support at livewithms.com
#LiveWithMS #MSAwareness #MultipleSclerosis #MSTreatment #InfusionTherapy #MSCare #ChronicIllnessSupport
Read the full guide here:
livewithms.com/blogs/blog/ultimate-guid...
More education and support at livewithms.com
#LiveWithMS #MSAwareness #MultipleSclerosis #MSTreatment #MSMedications #ChronicIllnessEducation #MSCommunity
A UK biology teacher is the first patient to receive a 'gamechanger' therapy for MS, marking a monumental leap forward for treatments and offering immense hope! #MSTreatment #MedicalBreakthrough #HopeForMS 🧬✨
Illustration of a winding path with colorful markers and a speech bubble stating, "New data offer a plausible timeline for how MS develops years before symptoms." "MultipleSclerosisNewsToday.com" is noted as source at bottom.
Recent findings could be a “game changer” for how we understand and manage MS. Explore how they might open new avenues to treat the disease at very early stages or even prevent it altogether: https://bit.ly/4oeVzk0
#MS #MultipleSclerosis #MSTreatment #MSNews #MSLife #LivingWithMS #Bionews
The Latest News: Two compounds show potential for myelin repair in MS, promising results in animal and cell models. Swipe to read more.
Megaphone and speech bubbles on a blue background. Text says, "One protein that has been identified as a potential target for promoting myelin repair in MS is the estrogen receptor beta (ER-beta), which is produced throughout the body, enabling cells to respond to certain hormones."
Megaphone and speech bubbles on blue background with text: "Data suggest that activating ER-beta in the brain can promote the production of new myelin." Swipe to read more.
Megaphone and speech bubbles with text, "In experiments done using cell models, K102 and K110 were shown to promote the growth and maturation of oligodendrocytes, the cells chiefly responsible for making and repairing myelin in the brain and spinal cord."
A recent study has unveiled two experimental compounds that show remyelination potential. See how this progress could redefine what we expect from future therapies: https://bit.ly/4hjg4ZT
#MS #MultipleSclerosis #MSResearch #MSTreatment #EndMS #MSNews #MSNewsToday #Bionews
Illustration of a thoughtful woman surrounded by puzzle pieces, with text asking about a breakthrough in myelin repair for MS. "MultipleSclerosisNewsToday.com" is noted as source at bottom.
ICYMI: New research could “help deliver on the promise of regenerative therapies that MS patients so urgently need.” See how: https://bit.ly/3IJPDzK
#MS #MultipleSclerosis #MSResearch #MSTreatment #MSCommunity #MyelinRepair #Remyelination #MSNews #Bionews
Two researchers discuss a medication while another person stands nearby. The text above reads as follows: "FDA pushes back tolebrutinib decision, now expected Dec. 28." "MultipleSclerosisNewsToday.com" is noted as source at bottom.
See why the FDA says it needs extra time to make a decision on the approval of the BTK inhibitor: https://bit.ly/47QDt2i
#MS #MultipleSclerosis #MSTreatment #MSResearch #MSCommunity #LivingWithMS #EndMS #MSNews #Bionews
Illustration of a woman injecting herself with medication. The above text reads, "A Phase 3 trial has begun testing an at-home injectable version of Briumvi." "MultipleSclerosisNewsToday.com" is noted as source at bottom.
If results are positive, the study could support the new formulation’s approval as early as 2028. It'd be the only anti-CD20 therapy offered as an intravenous infusion and a self-administered subcutaneous one. Learn more: https://bit.ly/42yObqz
#MS #MSTreatment #MSResearch #MSNews #ClinicalTrial
A graphic of a healthcare worker holding a mask to a patient's face. The following text appears above: "Glatiramer acetate products for RRMS may cause severe anaphylactic reactions, warns Health Canada." Key symptoms to look out for include difficulty breathing, swelling, dizziness, and rapid blood pressure drop. "MultipleSclerosisNewsToday.com" is noted as source at bottom.
The warning comes after 14 cases of anaphylaxis were tied to use of glatiramer acetate. See the specifics: https://bit.ly/4mVjWSR
#MS #MultipleSclerosis #MSTreatment #MSResearch #MSCommunity #MSNews #Bionews
Illustration of a thoughtful woman surrounded by puzzle pieces, with text asking about a breakthrough in myelin repair for MS. "MultipleSclerosisNewsToday.com" is noted as source at bottom.
New research could “help deliver on the promise of regenerative therapies that MS patients so urgently need.” See how: https://bit.ly/3JNmOmn
#MS #MultipleSclerosis #MSResearch #MSTreatment #MSCommunity #MyelinRepair #Remyelination #MSNews #Bionews
MS News Alert: UAE first to approve tolebrutinib for treating adults with nonrelapsing SPMS. "MultipleSclerosisNewsToday.com" is noted as source at bottom.
The oral BTK inhibitor is the first approved therapy to directly address the chronic inflammation that contributes to disability progression independent of relapses. See how it works: https://bit.ly/4lSD9Dw
#MS #MultipleSclerosis #MSNews #MSTreatment #MSCommunity #TherapyApproval #Bionews
A pharmacist stands next to a large pill bottle, highlighting that a generic version of Ampyra is available in the U.S. for under $40. "MultipleSclerosisNewsToday.com" is noted as source at bottom.
Dalfampridine was chosen as a priority product because of its high list price and “significant patient need.” Learn about other low-cost versions of high-priced drugs here: https://bit.ly/4g3Ov6m
#MS #MultipleSclerosis #MSTreatment #AffordableMeds #MSCommunity #MSNews #Bionews
Four people discuss data at a conference table, with a chart in the background. The text above reads, "A new tool called the MS Clinical and Imaging Data Resource aims to accelerate the search for effective treatments for progressive disease forms." "MultipleSclerosisNewsToday.com" is noted as source at bottom.
The resource is one of the largest collections of MS data ever assembled. See how its large pool of anonymized data will help researchers worldwide better understand MS progression: https://bit.ly/4mzYiTY
#MS #MSResearch #MSTreatment #MSNews #ProgressiveMS #PPMS #EndMS #Bionews
A young girl in a hospital waiting room holding a flower painting, with text above reading, "Clinical trial findings suggest that early high-efficacy treatment may be preferable in pediatric MS." "MultipleSclerosisNewsToday.com" is noted as source at bottom.
In one study, nearly half of patients on Copaxone and one-third of those on Avonex switched to a high-efficacy treatment because of partial disease control. Explore the findings in full: https://bit.ly/4mur9co
#MS #PediatricMS #MSResearch #MSTreatment #MSCommunity #MSNews #Bionews
New research has identified HLA-A∗03:01 as a predictive and genetic treatment biomarker for MS. See what the finding means for personalized disease treatment: https://bit.ly/4mCaP9O
#MS #MSTreatment #MSResearch #MSNews #MSCommunity #Bionews
Results from the trial’s randomized part are expected by the end of the year. See how obexelimab is thought to help in MS by targeting two B-cell proteins: https://bit.ly/4mJFcuj
#MS #MultipleSclerosis #MSTreatment #MSResearch #MSNews #ClinicalTrial #ClinicalResearch #Bionews
The signed agreement puts the oral therapy one step closer to a Phase 2 clinical trial. Learn how: https://bit.ly/45yUDP5
#MS #MultipleSclerosis #MSTreatment #MSResearch #MSNews #Bionews
A smiling patient lies in a hospital bed while receiving an infusion. The text above reads "For the first time ever, an MS patient has been treated with an "off-the-shelf" CAR T-cell therapy, azer-cel." "MultipleSclerosisNewsToday.com" is noted as source at bottom.
A first-of-its-kind Phase 1 trial in MS is “pushing boundaries carefully and thoughtfully to explore what could be possible.” See how: https://bit.ly/3Jvn3SE
#MS #MSTreatment #MSResearch #MSNews #ClinicalResearch #Bionews
Illustration of a doctor holding a pack of pills and a clipboard, with text about Lucid-MS seeking U.S. clearance for a Phase 2 MS study by the end of 2025. "MultipleSclerosisNewsToday.com" is noted as source at bottom.
Now that Lucid-MS has been found to be safe and well tolerated in healthy adults, its developer is preparing for the launch of MS efficacy trials. Learn about this “first-in-class … neuroprotective compound” here: https://bit.ly/45LdPua
#MS #MSResearch #MSTreatment #MSCommunity #MSNews #Bionews
Graphic titled "When to Consider Switching Your MS Therapy" with illustrations highlighting the following issues: adherence struggles, pregnancy, side effects and infections, financial issues, lack of efficacy, and lab test abnormalities. "MultipleSclerosisNewsToday" is noted as source at bottom.
It’s not uncommon to need to switch MS treatments. Here are a few factors you’ll want to consider as you work with your care team to find the right therapy for you: https://bit.ly/4ll1wtk
#MS #MSTreatment #MSCommunity #MSAwareness #Bionews
Preclinical findings show estradiol helped to reduce inflammation and nerve damage, resulting in fewer and less severe symptoms after six months. Explore the research: https://bit.ly/4opgPUl
#MS #MSResearch #MSTreatment #MSNews #MSAwareness #Bionews
Illustration of damaged myelin sheath with text highlighting remyelinating therapies' potential to promote neuroprotection in RRMS. "MultipleSclerosisNewsToday" is noted as source at bottom.
Researchers looked at data from a trial testing bexarotene, a cancer treatment, in MS. See what they found about the relationship between remyelination and nerve fiber damage: https://bit.ly/4lbu7B1
#MS #MSResearch #MSTreatment #MSNews #Remyelination #Bionews
In one study, 33% of patients had active disease pre-transplant. After a year, none of those with available data showed active disease. The low level was maintained after five years. Review the findings: http://bit.ly/41dgieg
#MS #MSTreatment #StemCellTransplant #MSResearch
Following one year of treatment, 90% of patients had no new lesions, relapses, or sustained disability progression. Catch up on all the findings: https://bit.ly/4lBmBR2
#MS #RelapsingMS #MSTreatment #MSResearch #MSNews #Bionews
Review new findings that show how induced neural stem cell grafts can turn into myelin-producing cells: https://bit.ly/40Pq1au
#MS #MSResearch #MSTreatment #MSNews #Bionews
A recent recommendation from her neurologist made no sense to Leigh Anne Nelson, a pharmacist herself who is “supposed to know everything about medications.” Now she’s reevaluating her treatment’s risk-to-benefit ratio. See why: https://bit.ly/44F9pVv
#MS #MSTreatment #LivingWithMS #ThisIsMS
While the MS treatment landscape has evolved in recent years, a cure for the disease doesn’t yet exist. Research continues to explore the potential of experimental therapies, like these: https://bit.ly/3GoEmnx
#MultipleSclerosis #MSTreatment #MSResearch #MSNews
Little is known about the neurotoxin’s effectiveness in treating conditions other than stroke, but new research shows satisfaction among those who have received it. Catch up on the findings: https://bit.ly/46BCtOI
#MS #MultipleSclerosis #MSTreatment #MSResearch #MSNews #Botox
